INAVOLISIB for Breast cancer metastatic: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 70 adverse event reports in the FDA FAERS database where INAVOLISIB was used for Breast cancer metastatic.
Most Reported Side Effects for INAVOLISIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Hyperglycaemia | 54 | 28.7% | 2 | 19 |
| Blood glucose increased | 28 | 14.9% | 0 | 9 |
| Diarrhoea | 21 | 11.2% | 1 | 10 |
| Stomatitis | 20 | 10.6% | 1 | 3 |
| Fatigue | 18 | 9.6% | 0 | 3 |
| Thrombocytopenia | 16 | 8.5% | 0 | 1 |
| Off label use | 14 | 7.5% | 2 | 6 |
| Diabetic ketoacidosis | 13 | 6.9% | 2 | 7 |
| Nausea | 13 | 6.9% | 0 | 3 |
| Neutropenia | 10 | 5.3% | 0 | 0 |
| Anaemia | 7 | 3.7% | 0 | 1 |
| White blood cell count decreased | 7 | 3.7% | 0 | 1 |
| Acute kidney injury | 6 | 3.2% | 0 | 5 |
| Asthenia | 6 | 3.2% | 0 | 1 |
| Death | 6 | 3.2% | 4 | 1 |
Other Indications for INAVOLISIB
Breast cancer (36)
Product used for unknown indication (30)
Breast cancer female (6)
Hormone receptor positive breast cancer (6)
Other Drugs Used for Breast cancer metastatic
PALBOCICLIB (18,160)
RIBOCICLIB (9,771)
LETROZOLE (6,856)
TRASTUZUMAB (6,303)
FULVESTRANT (4,570)
PERTUZUMAB (3,784)
CAPECITABINE (3,691)
PACLITAXEL (3,241)
DOCETAXEL (3,070)
EVEROLIMUS (2,751)